论文部分内容阅读
目的 :评价CEA、AFP、CA - 12 5联检对妇科肿瘤的诊治价值。方法 :测定采用放射免疫分析法。结果 :妇科恶性肿瘤中CA - 12 5阳性率 80 85 % (38/ 47) ;CEA阳性率 8 5 1% (4 / 47) ;AFP阳性率 14 89(7/ 47)。三项联检阳性检出率 95 7% (4 5 / 47)。妇科良性肿瘤CA - 12 5均值 2 2 0 2± 15 35 ,恶性肿瘤CA - 12 5均值2 13 5 9± 12 7 2 6 ,二者比较有显著性差异 (P <0 0 1)。术后CA - 12 5均值为 34 2 3± 2 0 5 2 ,与手术前 2 13 5 9±12 7 2 6比较P <0 0 1。结论 :CEA、AFP、CA - 12 5联检有助于提高妇科恶性肿瘤诊断符合率 ,CA - 12 5可作为术后长期追踪检测的指标。
Objective: To evaluate the diagnostic value of CEA, AFP and CA - 125 in gynecologic oncology. Methods: The determination of radioimmunoassay. Results: The positive rate of CA - 125 in gynecological malignant tumors was 80 85% (38/47). The positive rate of CEA was 851% (4/47). The positive rate of AFP was 14 89 (7/47). The positive rate of three positive tests was 95.7% (45/47). The average CA - 125 of gynecologic benign tumors was 2220 ± 1535, and the average CA - 125 of malignant tumors was 2 13 5 9 ± 12 7 2 6 (P <0.01). The average CA - 125 after operation was 34 2 3 ± 2 0 5 2, P <0.01 compared with 2 13 5 9 ± 12 7 2 6 before operation. Conclusion: The CEA, AFP and CA - 125 joint tests can help to improve the diagnostic accuracy of gynecological malignancies, and CA - 125 can be used as a long - term follow - up test.